ArticleJournal of neuro-oncology2019
Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system.
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EANS-EANO guidelines on the extent of resection in gliomas.Neuro-oncology · 2026Guideline
- Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma.Journal of neuro-oncology · 2026Article
- Revisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.European radiology · 2026Article
- Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.Journal of neuro-oncology · 2025Article
- Prediction of 1p/19q state in glioma by integrated deep learning method based on MRI radiomics.BMC cancer · 2025Article
- Survival prediction with radiomics for patients with IDH mutated lower-grade glioma.Journal of neuro-oncology · 2025Article
- Ultra-rapid droplet digital PCR enables intraoperative tumor quantification.Med (New York, N.Y.) · 2025Article
- Symptom management in isocitrate dehydrogenase mutant glioma.Neuro-oncology practice · 2025Review
- Prognostic impact of tumor size on cancer-specific survival for postoperative WHO grade II oligodendroglioma: a SEER-based study.Frontiers in surgery · 2025Article
- Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas.Frontiers in oncology · 2025Article
- Machine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma.Discover oncology · 2024Article
- Recursive partitioning analysis for survival stratification and early imaging prediction of molecular biomarker in glioma patients.BMC cancer · 2024Article
- Ultra-Rapid Droplet Digital PCR Enables Intraoperative Tumor Quantification.medRxiv : the preprint server for health sciences · 2024Article
- Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.BMC medical imaging · 2024Article
- Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.European radiology · 2024Article
- Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.Journal of neuro-oncology · 2023Article
- T2-FLAIR mismatch sign correlates withJournal of neuro-oncology · 2023Article
- Long-term follow up of patients with WHO grade 2 oligodendroglioma.Journal of neuro-oncology · 2023Article
- Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.Journal of neuro-oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccording to the 2016 WHO classification lower-grade gliomas consist of three groups: IDH-mutated and 1p/19q co-deleted, IDH-mutated and IDH-wildtype tumors. The aim of this study was to evaluate the impact of surgical therapy for lower-grade gliomas with a particular focus on the molecular subgroups.
methodsThis is a bi-centric retrospective analysis including 299 patients, who underwent treatment for lower-grade glioma between 1990 and 2016. All tumors were re-classified according to the 2016 WHO classification. Data concerning baseline and tumor characteristics, overall survival, different treatment modalities and functional outcome were analyzed.
resultsA total of 112 (37.5%) patients with IDH-mutation and 1p/19q co-deletetion, 86 (28.8%) patients with IDH-mutation and 101 (33.8%) patients with IDH-wildtype tumors were identified. The median overall survival (mOS) differed significantly between the groups (p < 0.001). Surgical resection was performed in 226 patients and showed significantly improved mOS compared to the biopsy group (p = 0.001). Gross total resection (GTR) was associated with better survival (p = 0.007) in the whole cohort as well as in the IDH-mutated and IDH-wildtype groups compared to partial resection or biopsy. IDH-wildtype patients presented a significant survival benefit after combined radio-chemotherapy compared to radio- or chemotherapy alone (p = 0.02). Good clinical status (NANO) was associated with longer OS (p = 0.001).
conclusionThe impact of surgical treatment on the outcome of lower-grade gliomas depends to a great extent on the molecular subtype of the tumors. Patients with more aggressive tumors (IDH-wildtype) seem to profit from more intensive treatment like GTR, multiple resections and combined radio-/chemotherapy.
Indexed as
Identifiers
30467813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.